Is Akebia Therapeutics (AKBA) One of the Best Penny Stocks to Buy [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
On February 26, Akebia Therapeutics Inc. (NASDAQ:AKBA) outlined its 2026 pipeline expansion and shared expectations for Vafseo data catalysts in the $1 billion dialysis market during its fourth quarter 2025 earnings call. The company reported a total of $227 million in net product revenue for the year, with Vafseo and Auryxia being major contributors. hywards/Shutterstock.com Chief Executive Officer John Butler reported that it was an important year for Akebia, particularly due to the commercialization of Vafseo. He also reported that there is increasing evidence of Vafseo's potential for becoming standard of care in what is a $1 billion U.S. opportunity post-TDAPA, when Vafseo is expected to be priced at about parity with ESA pricing. The company also announced its pipeline for rare kidney diseases, including an R&D day scheduled for April 2 to discuss mid-stage assets such as praliciguat and AKB-097. Butler stated: “At the ASN meeting in November, we presented a post-hoc hi
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026GlobeNewswire
- Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Details Vafseo Commercial Push, TIW Dosing Plans and Kidney Pipeline at Leerink Conference [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript [Seeking Alpha]Seeking Alpha
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/5/26 - Form 4
- 2/26/26 - Form 10-K
- AKBA's page on the SEC website